MSD’s Post

🔬 Swab Samples: Essential for Microbiome and Infectious Disease Studies 🔬 Swab samples are crucial for studying the microbiome and infectious diseases. At Caucasus Bioscience, we provide high-quality swabs that are collected with care to ensure their accuracy in research. Our samples support the development of new diagnostics and treatments that improve patient care. #CaucasusBioscience #MicrobiomeResearch #SwabSamples

“Macrophages is the last frontier!” If interested in taking a plunge into the world of immune related diseases; current and future treatments, the ACR Convergence 2023 – held in beautiful San Diego – is a good place to start. Cyxone is having busy days meeting with old and new friends at the ACR who share our excitement about exploring macrophage targeting – the last frontier… Follow Cyxone as we advance our macrophage selective Phase 2 candidate rabeximod in autoimmune/autoinflammatory diseases. #ACR23 #rheumatoidarthritis #autoimmunity

REMINDER!! EveryCat Health Foundation present "Feline Infectious Peritonitis: From the FCoV to FCoV23, The Cyprus Case or A New Perspective in the Way We See Coronaviruses," Date and Time: Saturday, February 3rd, 2024, at 11:00 am EST. https://bit.ly/FIP_Cyprus We have all heard about the developments in Cyprus relating to cats and Coronvirus. This webinar (comprehensive at 1.5-hours) webinar will follow the FCoV-23 outbreak in Cyprus from early 2023. The presenters are actively involved in the investigation, will describe the appearance of this outbreak, the differences in the clinical appearance of the “FCoV-23” , the findings from the polymerase chain reaction testing, and the whole genome analysis of PCR confirmed cases.

Before joining OM Pharma, I had limited knowledge about the rare disease we're tackling today. However, collaborating with Alexander Bienz, Alpha 1 Verein Schweiz and our incredible team has been eye-opening. Together, we've delved into understanding Alpha-1 Antitrypsin Deficiency (AATD), advocating for patients, and boosting awareness. Alpha-1 Antitrypsin Deficiency is a genetic condition 🧬 that can lead to lung, liver, and skin diseases. Why is this cause so important, you ask? Well, AATD is often diagnosed too late due to a lack of awareness, nonspecific symptoms often mistaken for other conditions, stigma surrounding lung disease, limited routine screening, and the absence of widespread genetic testing. Therefore, early detection is crucial and can improves lives. 🌍 Today marks the European Alpha-1 Awareness Day! Join us in our mission to raise awareness and support those affected by Alpha-1 Antitrypsin Deficiency. Learn more about the disease and how you can help: https://lnkd.in/euz3SdNq #unitedforalpha1 #raredisease #diseaseawareness

Infectious disease outbreaks continue to pose significant challenges to public health, and solutions are needed that enable real-time, comprehensive genomic characterisation of pathogens and antimicrobial resistance (#AMR). Check out our recent webinar to discover how rapid, accessible nanopore sequencing and BugSeq analysis is enabling swift and accurate investigation of bacterial community clusters, antimicrobial resistance profiling, and contributing to outbreak management. Watch here: <<https://lnkd.in/dwZqjsmn>>

Partnerships and collaborations are key to moving the needle forward towards more treatments for rare diseases. To mark Rare Disease Day 2024, Therapeutic Advances in Rare Disease and Therapeutic Advances in Infectious Disease are partnering to launch a new Special Collection. https://lnkd.in/e9nRbEdv #Rarediseases #TARareDisease #TherapeuticAdvancesInInfectiousDisease #Infectiousdisease #international

Microfluidic systems for infectious disease diagnostics T. Lehnert and M. A. M. Gijs, Lab Chip, 2024, 24, 1441 Infectious diseases are undeniably linked to the fate of human society. The current health system is facing growing challenges due to the fast and dynamic evolution of societal and environmental parameters that impact pathogen transmission, distribution and biological adaptation. Fast-spreading antibiotic resistance is a major emerging global health threat.   Our Tutorial Review explores how infectious disease diagnostics may benefit from innovative microfluidics and biosensor-based technologies. Have a look ! #microfluidics #biosensor #infectiousdiseases #lab-on-a-chip https://lnkd.in/e844WVC3

I'm very pleased to announce that my first paper has just been published! Myself, Robin N. Thompson (University of Oxford), Christian (Kit) Yates, and Ruth Bowness (both University of Bath as well as me) are proud to present 'Mathematical methods for scaling from within-host to population-scale in infectious disease systems', which has been published in Epidemics by Elsevier. Mathematical modellers model infectious disease dynamics at different scales. Within-host models represent the spread of pathogens inside an individual, whilst between-host models track transmission between individuals. However, pathogen dynamics at one scale affect those at another. This has led to the development of multiscale models that connect within-host and between-host dynamics. In this article, we systematically review the literature on multiscale infectious disease modelling according to PRISMA guidelines, dividing previously published models into five categories governing their methodological approaches (Garira (2017)), explaining their benefits and limitations. We provide a primer on developing multiscale models of infectious diseases. If you would like to read it, you can find it at the following link: https://lnkd.in/eEtjTP7k

RARE Disease Facts (Global Genes) #rarediseaseday2024 🦓 1 in 10: People are Affected by Rare Disease 🦓 1 in 2:  Rare Diseases Don’t Have a Foundation or Research Support Groups 🦓 1 of 2:  Patients Diagnosed with a Rare Disease is a Child 🦓 3 of 10:  Children with a Rare Disease Won’t Live to See Their 5th Birthday 🦓 400:  Million People Suffer From a Rare Disease Globally 🦓 8 in 10:  Rare Diseases are Genetic 🦓 4.8 Years:  The Average Time it Takes for Rare Patients to Receive an Accurate Diagnosis 🦓 95%: Rare Diseases Lack an FDA Approved Treatment 🦓 10,000+:  Distinct types of Rare and Genetic Diseases

Today marks Day 1 of the 5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Conference in London. Shahriar, Nicole and Haroon will be available on the stand to discuss all of your diagnostic requirements. #rbiopharm #rbiopharmrhone #ausdiagnostics #clinicaldiagnostics